Docket #: S21-454
Cell-permeant inhibitors of viral cysteine proteases
The coronavirus main protease (Mpro), which is a trypsin-like protease with a catalytic cysteine residue, processes viral proteins in an early step of the coronavirus life cycle, and its activity is required for viral replication. Mpro represents a promising drug target for treatment of coronavirus diseases.
Stanford researchers have designed and developed a set of small-molecule protease inhibitors that inhibit the SARSCoV2 main protease with improved cell permeation or potency.
Stage of Development
In vivo: Mouse Studies
Applications
- Therapeutic for SARSCoV2 infections
Advantages
- Administration via oral, subcutaneous, intramuscular, or IV routes
- Increased stability compared to Pfizer small-molecule coronavirus protease inhibitor, PF-07321332
Related Links
Patents
- Published Application: WO2023114516
- Published Application: 20250074938
Similar Technologies
-
PI-kinase inhibitors with broad spectrum anti-infective activity S10-441PI-kinase inhibitors with broad spectrum anti-infective activity
-
Gene Editing and Delivery of Myeloid cells To Promote Wound Healing S20-412Gene Editing and Delivery of Myeloid cells To Promote Wound Healing
-
A method for the construction of aminocyclobutanes from copper-catalyzed aqueous [2+2] cycloadditions of unactivated olefins S22-298A method for the construction of aminocyclobutanes from copper-catalyzed aqueous [2+2] cycloadditions of unactivated olefins